Skip to main content

Envoy Medical Inc

For the period ended Dec 31, 2023. Filed Apr 1, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Apr 1, 2024

COCH$6.92-2.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Power of Attorney (included on signature pages herein)

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Brent T. Lucas and David R. Wells and each or any one of them, his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments to this Report, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the United States Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons in the capacities and on the date indicated.

SignatureTitleDate
/s/ Brent T. LucasChief Executive Officer and DirectorApril 1, 2024
Brent T. Lucas(Principal Executive Officer)
/s/ David R. WellsChief Financial OfficerApril 1, 2024
David R. Wells(Principal Financial and Accounting Officer)
/s/ Charles R. BrynelsenDirectorApril 1, 2024
Charles R. Brynelsen
/s/ Whitney Haring-SmithDirectorApril 1, 2024
Dr. Whitney Haring-Smith
/s/ Glen A. TaylorDirectorApril 1, 2024
Glen A. Taylor
/s/ Mona PatelDirectorApril 1, 2024
Mona Patel
/s/ Janis Smith-GomezDirectorApril 1, 2024
Janis Smith-Gomez
/s/ Susan J. KantorDirectorApril 1, 2024
Susan J. Kantor
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.